deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT04044430

Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Phase I/II Trial of Encorafenib, Binimetinib, and Nivolumab in Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer

Sponsor: Bristol-Myers Squibb

Conditions Metastatic Colon Adenocarcinoma Metastatic Colorectal Adenocarcinoma Metastatic Microsatellite Stable Colorectal Carcinoma Metastatic Rectal Adenocarcinoma Stage III Colon Cancer Stage III Colorectal Cancer Stage III Rectal Cancer Stage IIIA Colon Cancer Stage IIIA Colorectal Cancer Stage IIIA Rectal Cancer Stage IIIB Colon Cancer Stage IIIB Colorectal Cancer Stage IIIB Rectal Cancer Stage IIIC Colon Cancer Stage IIIC Colorectal Cancer Stage IIIC Rectal Cancer Stage IV Colon Cancer Stage IV Colorectal Cancer Stage IV Rectal Cancer Stage IVA Colon Cancer Stage IVA Colorectal Cancer Stage IVA Rectal Cancer Stage IVB Colon Cancer Stage IVB Colorectal Cancer Stage IVB Rectal Cancer Stage IVC Colon Cancer Stage IVC Colorectal Cancer Stage IVC Rectal Cancer
Interventions Binimetinib Encorafenib Nivolumab Questionnaire Administration
Updated 13 times since 2019 Last updated: Jan 5, 2023 Started: Aug 31, 2020 Primary completion: Jul 31, 2022 Completion: Jul 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor funding

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

A PHASE1 clinical study on Metastatic Colon Adenocarcinoma and Metastatic Colorectal Adenocarcinoma, this trial is terminated or withdrawn. The trial is conducted by Bristol-Myers Squibb and has accumulated 13 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Feb 2020 · 3 months · monthly snapshot~Feb 2020 – ~Apr 2020 · 2 months · monthly snapshot~Apr 2020 – ~May 2020 · 30 days · monthly snapshot~May 2020 – ~Aug 2020 · 3 months · monthly snapshot~Aug 2020 – ~Oct 2020 · 2 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2022 · 13 months · monthly snapshot~May 2022 – ~Feb 2023 · 9 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 23 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  3. Feb 2023 — Jul 2024 [monthly]

    Terminated PHASE1

    Status: Active Not Recruiting → Terminated · Phase: PHASE1_PHASE2 → PHASE1

  4. May 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  5. Apr 2021 — May 2022 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

▶ Show 8 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  2. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  3. Aug 2020 — Oct 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. May 2020 — Aug 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2020 — May 2020 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  6. Feb 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  7. Nov 2019 — Feb 2020 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  8. Sep 2019 — Nov 2019 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Pfizer
  • University of California, San Francisco
Data source: University of California, San Francisco

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations